sulfasalazine has been researched along with Osteoarthritis, Knee in 3 studies
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.
Osteoarthritis, Knee: Noninflammatory degenerative disease of the knee joint consisting of three large categories: conditions that block normal synchronous movement, conditions that produce abnormal pathways of motion, and conditions that cause stress concentration resulting in changes to articular cartilage. (Crenshaw, Campbell's Operative Orthopaedics, 8th ed, p2019)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sulfasalazine (SSZ) is a system XC- inhibitor; SSZ was applied intra-articularly to study the function of system XC- in the development of OA in rats subjected to anterior cruciate ligament transection and medial meniscectomy (ACLT + MMx)." | 1.43 | Sulfasalazine attenuates ACL transection and medial menisectomy-induced cartilage destruction by inhibition of cystine/glutamate antiporter. ( Liu, CC; Tsai, RY; Tsai, WY; Wong, CS; Wu, JL, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tuure, L | 1 |
| Hämäläinen, M | 1 |
| Moilanen, T | 1 |
| Moilanen, E | 1 |
| Tsai, WY | 1 |
| Tsai, RY | 1 |
| Liu, CC | 1 |
| Wu, JL | 1 |
| Wong, CS | 1 |
| Lakey, RL | 1 |
| Cawston, TE | 1 |
3 other studies available for sulfasalazine and Osteoarthritis, Knee
| Article | Year |
|---|---|
Aurothiomalate inhibits the expression of mPGES-1 in primary human chondrocytes.
Topics: Antirheumatic Agents; Chondrocytes; Dexamethasone; Dinoprostone; Enzyme-Linked Immunosorbent Assay; | 2015 |
Sulfasalazine attenuates ACL transection and medial menisectomy-induced cartilage destruction by inhibition of cystine/glutamate antiporter.
Topics: Animals; Anterior Cruciate Ligament Injuries; Antiporters; Antirheumatic Agents; Cells, Cultured; Ch | 2016 |
Sulfasalazine blocks the release of proteoglycan and collagen from cytokine stimulated cartilage and down-regulates metalloproteinases.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Cartilage, Articular; Cattle | 2009 |